5 results on '"Giuseppina Mongelli"'
Search Results
2. Posterior reversible encephalopathy syndrome (PRES) in a 6-year-old child with nephrotic syndrome
- Author
-
Alessandra Marinari, MD, Anthea Bottoni, MD, Luca Stoppino, MD, Gianpaolo Grilli, MD, Lucia Soldano, MD, Anna Calò, MD, Matilde Cioccia, MD, Giuseppina Mongelli, MD, Barbara Santangelo, MD, Felice Sica, MD, and Angelo Campanozzi, MD
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Posterior reversible encephalopathy syndrome (PRES) is a variable etiology clinical syndrome with similar neuroimaging results and clinical symptoms. PRES can develop in both adults and children and is characterized by headaches, disorders of consciousness, seizures and especially focal visual disturbances, often associated with hypertensive state. In most cases, symptoms resolve without neurological consequences. The treatment strategy concerns early diagnosis and general measures to correct the underlying cause of PRES. Here, we report a case of PRES that occurs in a 6-year-old child with nephrotic syndrome.
- Published
- 2021
- Full Text
- View/download PDF
3. Treating Pediatric Asthma According Guidelines
- Author
-
Riccardina Tesse, Giorgia Borrelli, Giuseppina Mongelli, Violetta Mastrorilli, and Fabio Cardinale
- Subjects
asthma ,pharmacology ,guidelines ,asthma management ,children ,Pediatrics ,RJ1-570 - Abstract
Asthma is a common chronic inflammatory disorder of the lower respiratory airways in childhood. The management of asthma exacerbations and the disease control are major concerns for clinical practice. The Global Strategy for Asthma Management and Prevention, published by GINA, updated in 2017, the British Thoracic Society/Scottish Intercollegiate Guideline Network, revised in 2016, the National Institute for Health and Care Excellence asthma guideline consultation, available in 2017, are widely accepted documents, frequently implemented, with conflicting advices, and different conclusion on asthma definition and treatment. An International Consensus on Pediatric Asthma was carried out in 2012 by a Committee with expertise in the field, to critically review differences on current guidelines. In addition, the specific issue of treating severe and difficult asthma has been recently highlighted throughout the International European Respiratory Society/American Thoracic Society guidelines on severe asthma. The aim of this paper is to describe conventional treatments and some new therapeutic approaches to pediatric asthma according to guidelines, highlighting key aspects, and differences on proposed clinical recommendations for asthma management. Age specific therapy are proposed in steps, according to clinical severity and the level of disease control. If control is not achieved within 3 months, stepping-up should be considered; otherwise, if control is achieved after 3 months, stepping down may be considered. The most used drug classes of asthma medications are beta-2 adrenergic agonists, corticosteroids, and leukotriene modifiers. Intramuscolar triamcinolone has been used for severe asthma treatment. Chromones and xanthines have been extensively used in the past, but they have shown limits related to their efficacy and safety profile. Omalizumab, a monoclonal antibody against IgE, is an immunomodulatory biological agent, used as new drug in patients with confirmed IgE-mediated allergic asthma, only for patient's specific range of total IgE level. There are low evidences in the efficacy of metotrexate, as well as macrolide antibiotics in children with asthma. Antifungal agents are also not recommended in asthmatic patients. Non-pharmacological measures that may improve patient's quality of life should also be attempted. We conclude that treatment decisions on childhood asthma management should be critically made, pondering the differences suggested by agreed international consensus documents.
- Published
- 2018
- Full Text
- View/download PDF
4. Posterior reversible encephalopathy syndrome (PRES) in a 6-year-old child with nephrotic syndrome
- Author
-
Angelo Campanozzi, Alessandra Marinari, Gianpaolo Grilli, L. Soldano, Barbara Santangelo, Anthea Bottoni, Felice Sica, Luca Pio Stoppino, Anna Calò, Matilde Cioccia, and Giuseppina Mongelli
- Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine ,Pediatrics ,medicine.medical_specialty ,business.industry ,lcsh:R895-920 ,Case Report ,Disorders of consciousness ,Posterior reversible encephalopathy syndrome ,medicine.disease ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,Neuroimaging ,Etiology ,medicine ,Treatment strategy ,Radiology, Nuclear Medicine and imaging ,Headaches ,medicine.symptom ,business ,Clinical syndrome ,Nephrotic syndrome ,030217 neurology & neurosurgery - Abstract
Posterior reversible encephalopathy syndrome (PRES) is a variable etiology clinical syndrome with similar neuroimaging results and clinical symptoms. PRES can develop in both adults and children and is characterized by headaches, disorders of consciousness, seizures and especially focal visual disturbances, often associated with hypertensive state. In most cases, symptoms resolve without neurological consequences. The treatment strategy concerns early diagnosis and general measures to correct the underlying cause of PRES. Here, we report a case of PRES that occurs in a 6-year-old child with nephrotic syndrome.
- Published
- 2021
5. Treating Pediatric Asthma According Guidelines
- Author
-
Violetta Mastrorilli, Fabio Cardinale, Giuseppina Mongelli, Riccardina Tesse, and Giorgia Borrelli
- Subjects
medicine.medical_specialty ,Omalizumab ,Immunoglobulin E ,Asthma management ,Pediatrics ,03 medical and health sciences ,0302 clinical medicine ,Quality of life (healthcare) ,tiotropium ,children ,medicine ,anticholinergics ,030212 general & internal medicine ,guidelines ,Intensive care medicine ,Pediatric asthma ,Asthma ,Leukotriene ,biology ,General Commentary ,business.industry ,lcsh:RJ1-570 ,lung function ,lcsh:Pediatrics ,Guideline ,asthma ,medicine.disease ,respiratory tract diseases ,030228 respiratory system ,Pediatrics, Perinatology and Child Health ,biology.protein ,pharmacology ,business ,medicine.drug ,asthma management - Abstract
Asthma is a common chronic inflammatory disorder of the lower respiratory airways in childhood. The management of asthma exacerbations and the disease control are major concerns for clinical practice. The Global Strategy for Asthma Management and Prevention, published by GINA, updated in 2017, the British Thoracic Society/Scottish Intercollegiate Guideline Network, revised in 2016, the National Institute for Health and Care Excellence asthma guideline consultation, available in 2017, are widely accepted documents, frequently implemented, with conflicting advices, and different conclusion on asthma definition and treatment. An International Consensus on Pediatric Asthma was carried out in 2012 by a Committee with expertise in the field, to critically review differences on current guidelines. In addition, the specific issue of treating severe and difficult asthma has been recently highlighted throughout the International European Respiratory Society/American Thoracic Society guidelines on severe asthma. The aim of this paper is to describe conventional treatments and some new therapeutic approaches to pediatric asthma according to guidelines, highlighting key aspects, and differences on proposed clinical recommendations for asthma management. Age specific therapy are proposed in steps, according to clinical severity and the level of disease control. If control is not achieved within 3 months, stepping-up should be considered; otherwise, if control is achieved after 3 months, stepping down may be considered. The most used drug classes of asthma medications are beta-2 adrenergic agonists, corticosteroids, and leukotriene modifiers. Intramuscolar triamcinolone has been used for severe asthma treatment. Chromones and xanthines have been extensively used in the past, but they have shown limits related to their efficacy and safety profile. Omalizumab, a monoclonal antibody against IgE, is an immunomodulatory biological agent, used as new drug in patients with confirmed IgE-mediated allergic asthma, only for patient's specific range of total IgE level. There are low evidences in the efficacy of metotrexate, as well as macrolide antibiotics in children with asthma. Antifungal agents are also not recommended in asthmatic patients. Non-pharmacological measures that may improve patient's quality of life should also be attempted. We conclude that treatment decisions on childhood asthma management should be critically made, pondering the differences suggested by agreed international consensus documents.
- Published
- 2018
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.